{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:03:46Z","timestamp":1790334226078,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["U54 AT008909"],"award-info":[{"award-number":["U54 AT008909"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000063","name":"Office of Dietary Supplements","doi-asserted-by":"publisher","award":["U54 AT008909"],"award-info":[{"award-number":["U54 AT008909"]}],"id":[{"id":"10.13039\/100000063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dmd.2026.100375","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:46:24Z","timestamp":1784961984000},"page":"100375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of simulated exogenous and endogenous lipid microenvironments on cannabidiol disposition and cytochrome P450 2C19\u2013mediated drug interactions: New mechanistic insights"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6159-039X","authenticated-orcid":false,"given":"Aiden-Hung P.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fridah C.","family":"Rotich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja B.","family":"Cech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-1839","authenticated-orcid":false,"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.dmd.2026.100375_bib1","first-page":"597","article-title":"Prevalence of cannabis use around the world: a systematic review and meta-analysis, 2000\u20132024","volume":"6","author":"Wang","year":"2024","journal-title":"China CDC Wkly"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.amepre.2023.03.005","article-title":"Increasing use of cannabis for medical purposes among US residents, 2013\u20132020","volume":"65","author":"Rhee","year":"2023","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.dmd.2026.100375_bib3","series-title":"The Agriculture Improvement Act of 2018 (2018 farm bill), Pub. L. No. 115-334, \u00a7 297A(1), 132 Stat. 4490","year":"2018"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/syn.890010304","article-title":"Effects of a behaviorally active LHRH fragment and septal area stimulation on the activity of mediobasal hypothalamic neurons","volume":"1","author":"Dudley","year":"1987","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.dmd.2026.100375_bib5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.70219","article-title":"Clinical study to evaluate drug interactions of cannabidiol with citalopram and morphine in healthy adults","volume":"119","author":"Salcedo","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100375_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1208\/s12248-021-00616-7","article-title":"Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization","volume":"23","author":"Doohan","year":"2021","journal-title":"AAPS J"},{"issue":"10","key":"10.1016\/j.dmd.2026.100375_bib7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl","key":"10.1016\/j.dmd.2026.100375_bib9","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100375_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction\u2013associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.dmd.2026.100375_bib11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.dmd.2026.100375_bib12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100375_bib13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2026.100375_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2017.01.027","article-title":"Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w\/v) and in vitro-in vivo extrapolation of hepatic clearance","volume":"101","author":"Palacharla","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100375_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.21840","article-title":"In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice","volume":"31","author":"Li","year":"2017","journal-title":"J Biochem Mol Toxicol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100375_bib16","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1124\/dmd.115.065987","article-title":"High-throughput cytochrome P450 cocktail inhibition assay for assessing drug-drug and drug-botanical interactions","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100375_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105810","article-title":"An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes\u2014application to establishing CYP2C8 inhibitor selectivity","volume":"162","author":"Kahma","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100375_bib18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1124\/dmd.115.065086","article-title":"Milk thistle constituents inhibit raloxifene intestinal glucuronidation: a potential clinically relevant natural product\u2013drug interaction","volume":"43","author":"Gufford","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100375_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1124\/dmd.117.079491","article-title":"Identification of intestinal UDP-glucuronosyltransferase Inhibitors in green tea (Camellia sinensis) using a biochemometric approach: application to raloxifene as a test drug via in vitro to in vivo extrapolation","volume":"46","author":"Tian","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100375_bib20","series-title":"US Food and Drug Administration. M12 drug interaction studies: guidance for industry","year":"2023"},{"issue":"6","key":"10.1016\/j.dmd.2026.100375_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/2042098611422559","article-title":"Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1","volume":"2","author":"Polasek","year":"2011","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"10.1016\/j.dmd.2026.100375_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100375_bib23","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1124\/dmd.114.059451","article-title":"Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation","volume":"42","author":"Gufford","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100375_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","article-title":"A human hepatocellular in vitro model to investigate steatosis","volume":"165","author":"G\u00f3mez-Lech\u00f3n","year":"2007","journal-title":"Chem Biol Interact"},{"issue":"5","key":"10.1016\/j.dmd.2026.100375_bib25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1440-1746.2008.05733.x","article-title":"Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes","volume":"24","author":"Ricchi","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100375_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.119.086470","article-title":"Quantifying hepatic enzyme kinetics of (\u2013)-\u03949-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100375_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.122.001128","article-title":"A physiologically-based pharmacokinetic model for cannabidiol in healthy adults, hepatically-impaired adults, and children","volume":"51","author":"Bansal","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100375_bib28","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat Protoc"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/jpet.123.001681","article-title":"An integrative approach to elucidate mechanisms underlying the pharmacokinetic goldenseal-midazolam interaction: application of in vitro assays and physiologically based pharmacokinetic models to understand clinical observations","volume":"387","author":"Nguyen","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100375_bib30","first-page":"46","article-title":"US sales of herbal supplements increased by 5.4% in 2024","volume":"144","author":"Smith","year":"2025","journal-title":"HerbalGram"},{"key":"10.1016\/j.dmd.2026.100375_bib31","first-page":"64","article-title":"Total sales of herbal supplements in United States show steady growth","volume":"71","author":"Blumenthal","year":"2006","journal-title":"HerbalGram"},{"key":"10.1016\/j.dmd.2026.100375_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2019.05.001","article-title":"A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics","volume":"201","author":"Cox","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100375_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/pharmrev.120.000046","article-title":"Analgesic potential of terpenes derived from Cannabis sativa","volume":"73","author":"Liktor-Busa","year":"2021","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.dmd.2026.100375_bib34","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1089\/can.2024.0187","volume":"10","author":"Elder","year":"2025","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100375_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvp.13403","article-title":"Cannabidiol and cannabidiolic acid: preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein","volume":"47","author":"Court","year":"2024","journal-title":"J Vet Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100375_bib36","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.bcp.2008.03.004","article-title":"Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases","volume":"75","author":"Hardwick","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100375_bib37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2012.05.019","article-title":"Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis","volume":"57","author":"Abdelmegeed","year":"2012","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100375_bib38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100375_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108168","article-title":"Liver fatty acid binding protein FABP1 transfers substrates to cytochrome P450 4A11 for catalysis","volume":"301","author":"McCarty","year":"2025","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dmd.2026.100375_bib40","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2147\/DMSO.S449494","article-title":"A review: cytochrome P450 in alcoholic and non-alcoholic fatty liver disease","volume":"17","author":"Jiang","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib41","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100375_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bms.1200130206","article-title":"Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration","volume":"13","author":"Ohlsson","year":"1986","journal-title":"Biomed Environ Mass Spectrom"},{"issue":"11","key":"10.1016\/j.dmd.2026.100375_bib43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.dmd.2026.100375_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejpb.2020.06.021","article-title":"Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers","volume":"154","author":"Izgelov","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"10.1016\/j.dmd.2026.100375_bib45","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.dmd.2026.100375_bib46","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1038\/s41598-025-87621-4","article-title":"A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women","volume":"15","author":"Saals","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.21502","article-title":"Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states","volume":"98","author":"Clarysse","year":"2009","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100375_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmd.2026.100375_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2025.106053","article-title":"Assessment of intestinal absorption of five cannabinoids from an ethanolic CBD-rich hemp extract using Caco-2 cells in vitro","volume":"106","author":"Araujo","year":"2025","journal-title":"Toxicol In Vitro"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:16:42Z","timestamp":1790331402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0090955626006446"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100375","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of simulated exogenous and endogenous lipid microenvironments on cannabidiol disposition and cytochrome P450 2C19\u2013mediated drug interactions: New mechanistic insights","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100375"}}